This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08092/identifier/pdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08092/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08092/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/drug/DB08092/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/drug/DB08092/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08092
rdf:type
n5:Drug
n5:description
3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide is a solid. This compound belongs to the phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond. This drug targets mitogen-activated protein kinase 14.
n5:group
experimental
owl:sameAs
n8:DB08092 n11:DB08092
dcterms:title
3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
adms:identifier
n4:DB08092 n9:99444563 n10:LI3 n12:5326870 n14:4484163
n5:IUPAC-Name
n6:271B5D5C-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5D62-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5D61-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5D5E-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5D5F-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5D60-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5D5A-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5D5B-363D-11E5-9242-09173F13E4C5 n6:271B5D58-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5D59-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B5D68-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5D69-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5D63-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5D64-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5D66-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5D65-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5D67-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5D6E-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5D70-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5D71-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5D6D-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5D6C-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5D6F-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5D5D-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5D6A-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5D6B-363D-11E5-9242-09173F13E4C5